Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TRIB 
Trinity Biotech plc (TRIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TRIB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.45% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.10M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 0.94 | 52 Weeks Range 0.48 - 2.21 | Updated Date 10/17/2025 |
52 Weeks Range 0.48 - 2.21 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -51.64% | Operating Margin (TTM) -42.73% |
Management Effectiveness
Return on Assets (TTM) -10.53% | Return on Equity (TTM) -1913.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 99546988 | Price to Sales(TTM) 0.31 |
Enterprise Value 99546988 | Price to Sales(TTM) 0.31 | ||
Enterprise Value to Revenue 1.62 | Enterprise Value to EBITDA -6.06 | Shares Outstanding 3726404 | Shares Floating 324912600 |
Shares Outstanding 3726404 | Shares Floating 324912600 | ||
Percent Insiders 12.01 | Percent Institutions 14.17 |
Upturn AI SWOT
Trinity Biotech plc
Company Overview
History and Background
Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland. The company develops, manufactures, and markets diagnostic products, initially focusing on infectious diseases. Over time, it expanded its product portfolio through organic growth and acquisitions to include autoimmune, clinical chemistry, and point-of-care testing solutions.
Core Business Areas
- Point-of-Care: Develops and manufactures rapid diagnostic tests for use at the point of care, such as HIV and syphilis tests.
- Clinical Laboratory: Offers a range of diagnostic assays and reagents for use in clinical laboratories, including tests for infectious diseases, autoimmune disorders, and clinical chemistry.
Leadership and Structure
Trinity Biotech's leadership team consists of its CEO, CFO, and other key executives. The organizational structure is based on functional departments, including research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Uni-Gold HIV: A rapid HIV diagnostic test for point-of-care use. Competitors include Abbott, Roche, and bioMu00e9rieux. Revenue is difficult to determine accurately as Trinity Biotech does not break it down per product. Market share varies regionally but is significant in developing countries. Competitors: Abbott, Roche, bioMu00e9rieux.
- Premier Hb9210: A fully automated HbA1c analyzer for diabetes monitoring.Competitors include Siemens Healthineers, Roche, and Abbott. Revenue is difficult to determine accurately as Trinity Biotech does not break it down per product. Market share varies regionally but is significant in developing countries. Competitors: Siemens, Roche, Abbott.
Market Dynamics
Industry Overview
The in-vitro diagnostics market is experiencing growth due to factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements. The market is competitive, with large players and smaller niche companies.
Positioning
Trinity Biotech is positioned as a global provider of diagnostic products, with a focus on point-of-care and clinical laboratory testing. The company's competitive advantages include its established distribution network, diverse product portfolio, and focus on emerging markets.
Total Addressable Market (TAM)
The global in-vitro diagnostics market is estimated at $90+ billion. Trinity Biotech is positioned to capture a portion of this TAM through its specialized product offerings and market focus.
Upturn SWOT Analysis
Strengths
- Established distribution network
- Diverse product portfolio
- Focus on emerging markets
- Expertise in point-of-care diagnostics
Weaknesses
- Smaller scale compared to major competitors
- High debt load
- Fluctuations in operational performance
- Limited R&D budget compared to large players
Opportunities
- Expansion into new geographic markets
- Development of new diagnostic tests
- Strategic partnerships and acquisitions
- Increasing demand for point-of-care diagnostics
Threats
- Intense competition from larger players
- Regulatory changes in key markets
- Technological obsolescence
- Economic downturns in emerging markets
Competitors and Market Share
Key Competitors
- Abbott (ABT)
- Roche (RHHBY)
- Siemens Healthineers (SEMHF)
Competitive Landscape
Trinity Biotech competes with larger, more diversified companies. Its competitive advantages include its focus on niche markets and point-of-care diagnostics. However, it faces challenges in terms of scale and resources.
Major Acquisitions
FMC
- Year: 2000
- Acquisition Price (USD millions): 37.3
- Strategic Rationale: Diversifying the product portfolio and expanding into new markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven, with periods of rapid expansion followed by periods of stagnation.
Future Projections: Future growth prospects depend on the company's ability to successfully execute its strategic initiatives and capitalize on market opportunities. However, as a private company, such projections are unavailable
Recent Initiatives: It is difficult to assess recent initiatives, given Trinity Biotech's private status. Historically initiatives included new product launches and market expansion efforts.
Summary
Trinity Biotech, while possessing strengths in point-of-care diagnostics and a focus on emerging markets, has faced challenges related to its smaller scale, debt, and competition from larger players. The company's growth has been inconsistent, and its future prospects depend on successfully navigating the competitive landscape and capitalizing on opportunities in the diagnostics market. Monitoring economic conditions and regulatory changes in key markets is crucial. The decision to delist from the NASDAQ in 2023 has significantly changed its financial and information disclosure profile.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (historical)
- Market research reports
- Industry analysis
- Publicly available information
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is based on estimates and may not be precise. Trinity Biotech is now a privately held company, so information is limited.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trinity Biotech plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1995-08-18 | President, CEO, Company Secretary & Director Mr. John Gillard | ||
Sector Healthcare | Industry Medical Devices | Full time employees 401 | Website https://www.trinitybiotech.com |
Full time employees 401 | Website https://www.trinitybiotech.com | ||
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.